PATENT CLAIM ANALYSIS

Application Number: 16247497
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-06
Patent Classification: ["514", "398000"]

Abstract:
The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.

Claim (Index 1):
A method of treating a subject with bacterial vaginosis, comprising administering intravaginally to the subject a single dose metronidazole gel composition wherein the single dose metronidazole gel composition is administered once for a total of one day, and the single dose metronidazole gel composition comprises:\n i) 60-70 mg of metronidazole; ii) about 30% to about 60% of water by weight of the single dose metronidazole gel composition; iii) at least one mucoadhesive gelling polymer; and iv) about 30% to about 60% of at least one or more solvents that have a saturated metronidazole solubility at 25\u00b0 C. of at least 20 mg/g; and wherein the subject exhibits a Nugent score of less than 4 within 20 to 31 days following the single dose administration.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 99.0
- Lexical Diversity: 1.09091
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14921737', '13593386', '13536960', '10946133', '14311200']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7536766471042139
- 35 USC 102 Novelty (BERT): 0.6035106503408144
- Combined Prediction Score: 0.738660047427874
- Mean Citation Score: 392.823974
- Max Citation Score: 544.3213
- Similarity Product: 453.479958776474

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test